The treatment of choice is radiotherapy or surgical excision. Systemic treatment (usually melphalan and corticosteroids) should be given only to patients who have generalized skin lesions. A case of primary multiple cutaneous plasmacytoma has been treated with intralesional tumour necrosis factor-a with a marked reduction in tumour size .
The prognosis of primary cutaneous plasmacytoma is much more favourable than that of patients with secondary skin involvement associated with multiple myeloma, and seems to be related to the tumour burden . Analysis of
Was this article helpful?